ZZFIRST

OFFICIAL TITLE: A BIOMARKER–DISCOVERY PHASE II TRIAL OF ENZALUTAMIDE AND TALAZOPARIB (BMN 673) FOR THE TREATMENT OF METASTATIC HORMONE–NAÏVE PROSTATE CANCER. MEDOPP234 – ZZFIRST (EUDRACT# 2019-003096-20)

PROJECT DETAILS

THE PRIMARY GOAL IS TO EVALUATE THE ANTITUMOR ACTIVITY OF TALAZOPARIB (BMN 673) IN COMBINATION WITH ENZALUTAMIDE AND ADT -AS DETERMINED BY THE CONFIRMED PROSTATE-SPECIFIC ANTIGEN-COMPLETE RESPONSE (PSA-CR)- IN PATIENTS WITH METASTATIC HORMONE–NAÏVE PROSTATE CANCER (MHNPC).

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

(mHNPC)

II

54

10

Spain

Start up